Rodica-Aura Badea, Dr.

Biography

Papers

• Anghel SA, Badea RA, Chiritoiu G, Patriche DS, Alexandru PR, Pena FAnghel SA et al . "Novel luciferase-based GLP-1 reporter assay reveals naturally-occurring secretagogues", British journal of pharmacology, (2022)
  IF: 9.47AI: 1.62
• Szedlacsek HS, Bajusz D, Badea RA, Pop A, Bică CC, Ravasz L, Mittli D, Mátyás D, Necula-Petrăreanu G, Munteanu CVA, Papp I, Juhász G, Hritcu L, Keserű GM, Szedlacsek SE.Szedlacsek HS et al . "Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats", JOURNAL OF MEDICINAL CHEMISTRY 1520-4804(ISSN 0022-2623), (2021)
  IF: 7.45
• Mentel M, Ionescu AE, Puscalau-Girtu I, Helm MS, Badea RA, Rizzoli SO, Szedlacsek SEMentel M et al . "WDR1 is a novel EYA3 substrate and its dephosphorylation induces modifications of the cellular actin cytoskeleton", Scientific reports 8(1): 2910, (2018)
  
• Mentel M, Badea RA, Necula-Petrareanu G, Mallikarjuna ST, Ionescu AE, Szedlacsek SEMentel M et al . "Expression, Purification, and Kinetic Analysis of PTP Domains", Methods in molecular biology (Clifton, N.J.) 1447: 39-66, (2016)
  
• Mihaela Mentel, Rodica A. Badea, Georgiana Necula - Petrareanu, Sujay T. Mallikarjuna, Aura E. Ionescu, Stefan E. SzedlacsekMihaela Mentel et al . "Expression, Purification, and Kinetic Analysis of PTP Domains", pp 39- 66, Protein Tyrosine Phosphatases, Rafael Pulido, (2016).
  ISBN: 978-1-4939-3744-8

Grants

Compound for inhibition of certain signaling processes related to the evolution of the cognitive processes 2017-2018

Acronym: Ctr.327/27.03.2017/Company CRU SRL, Medical Services Company/ Dunakesz, Hungary

Budget: 70.000 euro

Project director: Stefan Szedlacsek

Molecular modeling of a set of peptides that can disrupt the GluA2-Cterm complex with STEP (Complex A) or BRAG2 (ComplexB).

Novel radiolabeled affibodies for targeted imaging and therapy 2019-2022

Acronym: Bilateral agreement no.3698/13.09.2018 Romanian Academy- Hungarian Academy of Sciences

Project director: Stefan Szedlacsek

The project is agreed as a joint collaboration among IBAR and ATOMKI, UD and IFIN-HH is a cost free participant. There are two main directions envisaged by the proposed project: receptors mapping and therapy, using an affibody against HER2 receptor, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establish labeling procedures; c) ex vivo and/or in vivo testing of optimal compounds.

Structure, Regulation, and Biological Function 2007-2011

Acronym: PTPNET

Budget: 145.231,18 euro

Project director: Stefan Szedlacsek

Enzymatic characterization of both mEya3 and hEya1 to identify the similarities and differences between these two proteins with relatively low sequence homology.

“Reconstruction of Ancestor of Receptor Protein Tyrosine Phosphatase Catalytic” 2011-2016

Acronym: PN-II-ID-PCE-2011-3-0743

Budget: 1499990

Project director: Stefan Szedlacsek

Synthesis of the catalytic domain of ancestral PTP and its characterization both in vitro and in vivo.